Resveratrol for Improved Performance in the Elderly (RIPE)

University of Florida

Status and phase

Completed

Phase 1

Conditions

Memory

Treatments

Drug: High dose Resveratrol

Drug: Low dose Resveratrol

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01126229

238-2009

Details and patient eligibility

About

The investigators aim to conduct a randomized placebo controlled pilot study to determine whether resveratrol, a dietary ingredient, supplementation is safe and improves memory and physical performance in older adults. Loss in memory and physical performance is a frequent complaint in older adults and a growing public health issue. Additionally, later adulthood is associated with a normative decline in both working and primary memory as well as domains including attention, speed of processing and executive function. Resveratrol is safely tolerated in pre-clinical models and in dose-escalation human studies. It also has demonstrated beneficial effects on memory and performance in pre-clinical models. Therefore, this study will take the next step in understanding the longer-term safety (3 months) and efficacy of resveratrol supplementation on age-related health conditions.

Full description

Enrolled participants will complete psychological questionnaires and a multi-measure cognitive test battery, physical function, as well as provide blood samples, to determine blood chemistry. These will include complete blood count and complete metabolic count [(Na, K, Cl, CO2, BUN, Creatinine, Glucose, Total Protein, Albumin, Calcium, Phosphorous, Aspartate Aminotransferase (AST), Alkaline Phos, Total Bilirubin, and Alanine Amino Transferase (ALT)] and any others deemed necessary by the study physician. They will return to the laboratory to perform a muscular endurance test and MRI evaluation at the Brain Institute. Eligible participants will be randomly assigned with equal probability to either receive resveratrol (300 mg/d or 1000 mg/d) or placebo for twelve weeks. Immediately following completion of the MRI, participants will be given a month's supply of resveratrol or placebo. All participants will be closely monitored for safety and toxicity during the first 10 days (range 8-12 days are acceptable) of the trial. During this initial evaluation period, blood chemistries (complete metabolic profiles) will be evaluated every 3 (range 1-2 days are acceptable) days. Following one month, participants will be asked to return to clinic. At their monthly visits, memory tests, blood samples will be collected to monitor cognitive adaptations and ensure that no adverse changes have occurred. Participants' compliance with the supplementation regimen will also be checked through pill counts, and participants will be given a month's supply of product at each of their monthly visits. After 12 weeks of taking either resveratrol or a placebo on a daily basis, participants will complete a final test battery, an MRI scan, a blood draw collection. A follow-up evaluation will be provided at 10 and 30 days following completion of the final post-treatment assessment.

Enrollment

32 patients

Sex

All

Ages

65+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Men and women aged 65-100 years
Body mass index > = 25 and < = 35
Willing and able to participate in all aspects of the study
Willing to be randomized to either treatment group
Sedentary to moderately active lifestyle (<120 min aerobic activity/week)
Report of ability to walk one mile
MMSE > 24
Non-smoking
Telephone Interview for cognitive status (TICS)

Exclusion criteria

Active treatment for cancer, stroke (< 6 mo), peripheral vascular disease, coronary artery disease (myocardial infarction <6 mo), state III, IV Congestive Heart Failure, valvular heart disease, major psychiatric disease, severe anemia, liver or renal disease, diabetes, severe osteoarthritis, blindness or deafness, fracture in upper or lower extremity within the last 6 months, upper or lower extremity amputation, anticoagulant therapy (aspirin use is permitted), parkinsons disease
Failure to give consent
Anabolic medications (growth hormone or testosterone)
High amounts of physical activity (i.e. running, bicycling etc) > 120 min/week.
Dementing illness
Excessive alcohol use (>2 drinks per day)
Resting heart rate > 120 bpm
Systolic blood pressure > 180 mmHg
Diastolic blood pressure > 100 mmHg
Dietary supplementation of grape seed extract or ginko biloba
History of significant head injury
Vision or hearing impairment
Anticholinesterase inhibitor (such as Aricept)
Contraindications to MRI (e.g. cardiac pacemaker, implanted cardiac defibrillator, aneurysm clip, claustrophobia, etc.)
Consumption of red wine/dealcoholized red wine/red or purple grape juice more than once weekly; consumption of any dietary supplements containing resveratrol, quercetin, or P. cuspidatum in the previous 90 days;
Subject is participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment
Current Use of Antidepressant Medications
CES-D Score > 20